A recent paper published in Lancet Oncology examines drugs that target biological mechanisms in multiple myeloma. This article is the second of three articles discussing new drugs for myeloma treatment.

Researchers have begun to understand the multi-step process by which myeloma occurs. Key features of this process are signaling pathways, which take information from outside of the cell and from within the cell to create a cascading reaction. While signaling pathways are a part of all cells, they are problematic if not regulated.

Studies have shown that a pathway involving the NFkB …